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Abstract
Background: To study whether hypoxia influences the stem-like properties of ovarian cancer cells and their
biological behavior under hypoxia.
Method: Ovarian cancer cell lines ES-2 and OVCAR-3 were cultivated in different oxygen tensions for proliferation,
cell cycling and invasion analyses. The clonogenic potential of cells was examined by colony formation and sphere
formation assays. Stem cell surface markers, SP and CD44bright and CD44dim cells were analyzed by flow cytometry.
Protein expression of HIF-1α, HIF-2α, Ot3/4 and Sox2 were investigated by Western blotting.
Results: Both cell lines cultivated at hypoxic condition grew relatively slowly with extended G0/G1 phase. However,
if the cells were pre-treated under 1% O2 for 48 hrs before brought back to normoxia, the cells showed significantly
higher proliferation rate with higher infiltration capability, and significant more colonies and spheres, in comparison
to the cells always cultivated under normoxia. CD44bright cells expressed significantly higher levels of Oct3/4 and
Sox2 than the CD44dim cells and formed significantly more clones and spheres examined in vitro. Hypoxic
treatment of the cells resulted in stronger CD44 expression in both cell lines, and stronger CD133 expression in the
OVCAR-3 cell line. In parallel with these findings, significantly increased number of side population (SP) cells and
up-regulated expression of Oct3/4 and Sox2 in both ES-2 and OVCAR-3 cell lines were observed.
Conclusion: We conclude that ovarian cancer cells survive hypoxia by upgrading their stem-like properties through
up-regulation of stemness-related factors and behave more aggressively when brought back to higher oxygen
environment.
Background
Hypoxic microenvironments are frequently found in many
solid tumors including breast cancer, prostate cancer, brain
tumor, malignant melanomas, metastatic liver cancer and
ovarian cancer [1-5]. Solid tumors frequently encounter hyp-
oxic stress. Rapidly proliferating cancer cells may outgrow
their vascular network and limiting O2 diffusion within the
tumors. Hypoxic stress can also be caused by perfusion
defects as a result of abnormal tumor blood vessel structure
and function [6]. Hypoxia not only accounts for tissue
necrosis but also has a strong impact on tumor cell biology,
with a decreased sensitivity to apoptotic and other cell-death
signals, and increased signaling to promote angiogenesis,
proliferation and systemic metastasis capacity [7]. Tumor
hypoxia is not only a major problem for radiation therapy,
but it has also been implicated in the development of resist-
ance to many conventional chemotherapeutic agents [8,9].
The cancer stem cells particularly have been demonstrated
to escape from the radiotherapy and chemotherapy and are
able to form metastatic tumor in other organs. Several som-
atic tumors including ovarian tumors are considered to con-
tain a small subset of stem-like cells called cancer stem cells,
which have the capacity to self-renewal, differentiate and ini-
tiate new tumor [10-17].
The hypoxia inducible factors (HIFs) can be regulated by
oxygen availability. HIFs are recognized as key modulators
of the transcriptional response to hypoxic stress. Besides its
adaptive function in cellular stress responses, recent work
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has also revealed important roles for HIFs in both physio-
logical and pathological processes [6]. Increasing evidence
indicates that HIFs regulate a number of genes including
glucose metabolism, cell survival, erythropoiesis, stem cell
maintenance, angiogenesis related markers and resistance to
chemotherapy and radiation therapy [18]. Embryonic stem
cell markers, the transcription factors Oct3/4 (also called
POU5F1) and Sox2 have a pivotal role in the mainten-
ance of self-renewal of embryonic stem cells and primor-
dial germ cells. Oct3/4 is a homeodomain transcription
factor of the POU family. Some laboratories found that the
expression of Oct3/4 and Sox2 has an important role in
cancer cells survival, self-renew, differentiation and prolif-
eration in different somatic tumors such as lung, gastric,
colorectal, rectal, bladder, breast, prostate and ovarian can-
cers [19-21].
In addition, cancer stem cells typically represent a small
number of the total tumor cells which can be enriched on
the basis of cell surface maker expression. Several surface
markers have been reported to be associated with cancer
stem-like or progenitor cells. In the ovarian cancer, the early
progenitor cells are associated with some specific surface
markers like CD44, CD133 and CD117 [22-26]. However,
CD44+ and CD133+ subpopulations in ovarian cancer was
believed to be heterogeneous and consisted of progenitor
cells and differentiated cells as well [24,27].
Previously, SP cells have been found with some properties
of cancer stem cells [28,29] and cancer stem cells also ex-
press ATP-binding cassette glycoprotein transporters on
their surface. These transporters effectively pump out vital
dyes, resulting in a characteristic unlabeled side population
of cells detected in fluorescence activated cell sorting FACS
plot.
The effect of hypoxia on the cancer stem-like characteristics
of ovarian cancer cells has not been fully elucidated. There-
fore, the aim of this study was to examine whether hypoxia
can influence stem-like properties of ovarian cancer cell lines
in vitro with the methods of proliferation assay, cell cycle ana-
lysis, infiltration assay, colony formation assay, sphere forma-
tion assay, SP, FACS and Western blotting. It was repeatedly
shown that ovarian cancer cell lines OVCAR-3 and ES-2
under hypoxia exhibit significantly higher levels of stem-like
features in vitro.
Materials and methods
Cell lines and cell cultures
Human ovarian cancer cell lines ES-2 and OVCAR-3 were
purchased from American Type Culture Collection (ATCC,
Manassas, VA, USA) and maintained in our lab for this study.
For conventional cell culture, 2×105 cells were seeded in
25 cm2 culture flasks and maintained in RPMI 1640 medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (Invitrogen) and 100units/ml penicillin and
100 μg/ml streptomycin in a humidified 5% CO2 incubators
at 37 °C.
Hypoxic cell cultures
The Xvivo Closed Incubation System (XVIVO system
300 C, Biospherix, USA) was used in this study to obtain ac-
curate oxygen tensions in different incubators. After 24 hrs
cultivation in conventional cell culture (allowing cells to at-
tach onto the flasks), the cells were transferred into different
chambers with different oxygen controls for variable period
of culture before the cells were harvested for additional
examinations including MTT, sphere and colony formation
assays, cell cycle analyses, flow cytometry analyses, Western
blotting, SP and FACS.
MTT assay
For evaluation of hypoxia influence on proliferation of cells,
2000 cells/well in 180 μl of complete RPMI-1640 medium
were seeded into 96-well microplates under either normoxic
(20% O2) or hypoxic (1% O2) conditions for variable time
periods of culture before MTTanalyses. In addition, to study
whether hypoxia pretreatment influences the proliferation of
cells differently, the cells were firstly pretreated under nor-
moxic (20% O2) or hypoxic (1% O2) condition for 48 hrs be-
fore the cells were re-harvested and then cultured under
normoxia for periods of times before MTT assay. After the
cells in culture reached their time schedule, 5 mg/ml of 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromides
(MTT, Sigma-Aldrich, St. Louis, MO;USA) was added and
incubated at 37 °C for 4 hrs before 150 μL of dimethyl sulf-
oxide (DMSO) (Sigma-Aldrich) was added to each well and
mixed thoroughly. The plates were then shaken for 15 min
and absorbance was determined using a spectrophotometer
at a wavelength of 490 nm (μQuant; Bio-Tek Instruments,
Winooski, VT,USA).
Cell cycle analysis
Cells were cultivated under hypoxia or normoxia for 48 hrs,
and then harvested into 15 ml sterile conicaltubes, centri-
fuged and washed with ice-cold PBS. After cell counting,
1×106 cells were fixed in 70% ethanol for 24 hrs at −20 °C,
washed with cold PBS and re-suspended in PBS buffer con-
taining 50 μg/ml of PI and 100 units/ml of RNase type A.
The cells were then incubated in dark for 30 min at room
temperature. Samples were filtered using a 70 μm nylon
membrane and analyzed with an LSRII flow cytometer (Bec-
ton Dickinson, San Jose, CA, USA) after gating was opti-
mized. Data were analyzed with the FlowJo software
(Version 7.6).
Invasion assay
The invasion assay was performed with 24-transwell cham-
bers (Costar, Bodenheim, Germany), as previously described
[30]. Briefly, 1x104 cells were harvested and re-suspended in
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200 μl RPMI-1640 medium without serum before plated in
the top chamber. The lower chamber of the transwell was
filled with 500 μl RPMI-1640 medium supplemented with
10% fetal bovine serum. The cell suspension was applied
onto the matrigel membrane and incubated at 37 °C for
24 hrs. The cells migrated through the matrigel and the filter
were fixed with 70% methanol, stained with 0.2% crystal vio-
let, washed with ddH2O and counted under microscopy.
Sphere formation assay
Sphere formation assay was performed based on the previ-
ously described method [31]. The ES-2 and OVCAR-3 cells
were plated at different oxygen tensions for 48 hrs, and then
dispatched from cell culture flask and harvested. Single cells
(1000 cells per well) were re-plated and cultivated under nor-
moxia at ultralow attachment six-well plates (ultra low cluster
plates, Life sciences). These cells were cultivated for 14 days
under normoxic condition before the spheres were evaluated
under inverse miscopy and counted (more than 30 cells
within a sphere was considered to be a full sphere). In
addition, sphere formation assays of single CD44bright and
CD44dim cells (800 cells per well) were also performed with
the method as described above. All the experiments were
repeated three times.
Colony formation assay
The cells in 80% confluent were cultivated in different oxy-
gen conditions for 48 hrs and then washed with PBS and
dispatched from cell culture flask, harvested and counted
with the Countess Cell Counter (Invitrogen). 500 cells/well
were plated in 6-well plates and placed at 20% oxygen ten-
sion for 14 days, and the colonies were fixed with 4% buf-
fered formalin for 15 min and then stained with 1% crystal
violet for 30 min. The plates were gently washed with PBS
and dried before colony evaluation under microscopy. In
addition, the CD44bright and CD44dim cells (500 cells/well)
were also performed by colony formation assay with the
method as described above. Colonies which contained more
than 30 cells was counted. Colony formation efficiency was
calculated as following: colony numbers/seed cells number×
100%. Data are representative of three independent
experiments.
Flow cytometry and FACS
After 48 hrs incubation under hypoxia (1% O2) or normoxia
(20% O2), the cells were trypsinized, counted and washed with
cold FACS buffer (PBS+BSA 0.02%) with final concentration
of 1×106 cells/tube. The cells were pre-blocked with 0.5%
BSA for 30 min on ice before incubation for 30 min in the
dark, on ice with CD44 monoclonal antibody directly conju-
gated with allophycoyanin (APC) and CD133 monoclonal
antibody directly conjugated with fluorescein isothiocyanate
(FITC) both obtained from BD Pharmingen Company. Fol-
lowing washing twice with ice-cold PBS, the cell suspensions
in 800 μl FACS buffer were filtered through a 70 mm nylon
mesh. Samples were analyzed on a LSRII flow cytometer
(Becton Dickinson, San Jose, CA, USA). Viable and single
cells were gated for each sample acquired and APC Mouse
IgG2b and FITC Mouse IgG2b (both from BD Pharmingen,
USA) were used as negative control. The experiments were
performed at three independent times. Data were analyzed
using FlowJo software (Version 7.6).
For FACS, the cells were dissociated to viable single cell
suspensions and stained with CD44 monoclonal antibody
directly conjugated with APC as described above. Corre-
sponding non-immune isotype was included as negative
control. Top 10% CD44+ were separated with FACS and
determined as CD44bright cells and bottom 10% of CD44-
cells were separated with FACS and determined as
CD44dim cells. FACS was performed with a FACSAria flow
cytometer (Becton Dickinson).
SP analysis
For SP analysis, 1×106 cells were suspended in pre-warmed
RPMI 1640 medium containing 2% fetal bovine serum and
2 mM HEPES buffer. Hoechst 33342 dye (Sigma-Aldrich)
was added to a final concentration of 5 μg/ml from a stock
solution of 1 mg/ml in presence or absence of verapamil
(50 μM; Sigma) and incubated at 37 °C for 90 min with inter-
mittent shaking. At the end of the incubation, the cells were
washed with ice-cold HBSS with 2% FBS, centrifuged at 4 °C
and re-suspended in ice-cold HBSS containing 2% FBS. Propi-
dium iodide at a final concentration of 2 μg/ml was added to
the cells to gate viable cells. The cells were filtered through a
70-μm cell strainer to obtain single cell suspension before
analyzed with a LSRII flow cytometer (BD Biosciences, Frank-
lin Lakes, NJ, USA). Cell aggregates were discarded from the
analysis by doublet discrimination. SP cells were visualized or
sorted by use of red (blue, 402–446 nm) vs blue (red, 650–
670) ultraviolet channels both in linear mode.
Western blot analysis
Cultured cells were harvested and lysed with 200 μl of
whole cell protein RIPA buffer (25 mM Tris HCl pH 7.6,
100 mM NaCl, 1% NP40, 1% Sodium deoxycholate, 0.1%
SDS, Thermo Scientific Pierce, Bonn, Germany) with
added freshly prepared proteinase inhibitors (0.1 μM
Aprotinin, 1.0 mM PMSF, 1 μM Leupeptin, 1 μM Pepsta-
tin), and then the samples were frozen at −70 °C for
30 min. The samples were centrifuged at 15,000 rpm for
15 min at 4 °C and the supernatants were transferred to
new tubes. The protein concentrations were measured
with Bio-Rad protein assay (Hercules, CA, USA) accord-
ing to the manufacturer’s instruction. After heated with a
benchtop heater (Model 111002, Boekel Scientific, Feast-
erville, PA, USA) at 100 °C for 5 min in SDS-loading buf-
fer (500 mM Tris HCl pH 6.8; 10% Glycerol, 2% SDS,
0.6 M DTT, 0.05% Bromphenol blue), 50 μg protein per
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sample was subjected to 10% SDS-PAGE and transferred
to polyvinylidene difluoride transfer membrane (Bio-Rad).
Membranes were blocked with 5% non-fat dry milk in
0.05% TBS-Tween for 90 min at room temperature and
incubated overnight at 4 °C with the primary antibodies
against GAPDH (0.2 μg/ml), Oct3/4 (1 μg/ml), Sox2
(1 μg/ml), HIF-1α (1 μg/ml) and HIF-2α (1 μg/ml) all
from R&D Systems, Minneapolis, MN, USA. The mem-
branes were then incubated with corresponding secondary
HRP-conjugated antibodies including anti-goat IgG-
HRP antibody (1:2000) or anti-mouse IgG-HRP anti-
body (1:1000) all from R&D Systems, Minneapolis, MN,
USA. Immuno-complexes were visualized by enhanced
chemiluminescence (GE Healthcare, Bucks, and UK).
The western blotting experiments were repeated at least
three times.
Statistical analyses
Data are shown as mean±SEM of at least 3 experiments for
each experiment. SPSS software (version 16.0) was used for
data analysis. Statistical analysis was performed using Stu-
dent’sT test (P< 0.05 was considered statistically significant.
Results
Hypoxia results in comparatively slower growth rate with
extended G0/G1 cell cycle
ES-2 and OVCAR-3 ovarian cancer cell lines were cultivated
under either hypoxia or normoxia for periods of times by
MTT assay to investigate the effect of hypoxia on cell
growth. As shown in Figure 1A, the cells cultivated under
1% O2 (hypoxia) grew relatively slowly than the cells culti-
vated under normoxia (P< 0.01), although the growth
difference was not so apparent in the first 48 hrs, indi-
cating that the cell growth was inhibited under hypoxic
condition. The cells cultivated under either hypoxia or
normoxia were then examined with cell cycle analysis. It
could be repeatedly shown that there was significantly in-
creasing number of G0/G1 phase cells in the OVCAR-3
and ES-2 cells, from 50.8±6.2% and 53.17±1.98% in the
cells cultivated under normoxia compared to 74.1±4.5%
Figure 1 Hypoxia extended G0/G1 status with relatively slow growth of cells. Both OVCAR-3 and ES-2 cells were maintained under either
hypoxia or normoxia for variable periods of times. (A) Growth curves show that the cells under hypoxia grew relatively slower than those cells
under normoxia (P< 0.01). (B) Cell cycle analyses show extended G0/G1 phase in the cells cultivated under hypoxia, and the corresponding
histogram shows statistically significantly increased G0/G1 stage in both cell lines (P< 0.01 for OVCAR-3 and P< 0.05 for ES-2).
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and 71.44±6.6% in the cells cultivated under hypoxia, re-
spectively (Figure 1B). As shown in the histogram, there
was statistically significant difference for G0/G1 stage in
both cell lines (P< 0.01 for OVCAR-3 and P< 0.05 for
ES-2), indicating more quiescent cells under hypoxia
condition.
Hypoxic pretreatment promotes cell proliferation and
invasion
To explore how hypoxia-pretreatment influenced the bio-
logical behaviors of the cells, proliferation and invasion
assays were performed. As shown in Figure 2A, all the hyp-
oxia pretreated cells grow faster than those control cells al-
ways cultivated in normoxia. When the cells were
pretreated under hypoxia for 48 hrs and then cultivated
under normoxia, MTT values of both cell lines were sig-
nificantly higher than those cells always kept under nor-
moxia (P< 0.05). Furthermore, our invasive assays
revealed significantly higher number of invasive cells in the
hypoxia pretreated cells, both in the OVCAR-3 and ES-2
cells. As shown in Figure 2B, there are 2.9-fold increase in
number of invasive cells in the OVCAR-3 cells under hyp-
oxia and 3.5-fold increase in number of invasive cells in the
ES-2 cells under hypoxia (P< 0.0001 for both cell lines).
Hypoxia increases sphere and colony formation capability
of the cells
Under normoxia condition, spheres could be observed in
both cell lines (Figure 3A). Comparatively, hypoxia pretreat-
ment increased the number of spheres, with 1.96-fold in-
crease in the VCAR-3 cells and 1.59-fold increase in the ES-
2 cells (Figure 3B). The cells with hypoxia pretreatment were
also examined with the colony formation assay. Compared
with the cells always kept in normoxia, more colonies were
observed in the hypoxia pretreated cells (Figure 3C), with
2.38-fold increase in the OVCAR-3 cells and 2.86-fold in-
crease in the ES-2 cells, respectively (Figure 3D).
Hypoxia upregulates the expression of CD44 and CD133
The surface markers CD44 and CD133 were examined by
flow cytometry in consideration of the effect of hypoxia.
There were 1.99-fold increase in CD44 expression in the
OVCAR-3 cells under hypoxia and 2.73 fold increase in
CD44 expression in the hypoxia cultivated ES-2 cells
(Figure 4A). CD133 expression in the OVCAR-3 cells was
also increased with 1.48-fold, while almost no change was
observed in the ES-2 cells under hypoxia (Figure 4B). All
these data indicate that hypoxia induces the expression of
CD44 expression in these cell lines, and also positively
Figure 2 Hypoxia pretreatment induced cell proliferation and invasion potential. All the cells were cultivated under either hypoxia or
normoxia for 48 hrs before brought back to normoxia condition for proliferation or invasion assays. (A) The cells with hypoxia pretreatment for
48 hrs show significantly faster in growth than the cells always cultivated under normoxia (P< 0.05). (B) Cell invasion assays show that there are
significantly more infiltrated cells in the hypoxia pretreated groups than those in the normoxia control groups in both cell lines (P< 0.0001).
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influences the expression of CD133, at least in the
OVCAR-3 cells.
Hypoxia enriches SP cells
To determine whether hypoxia affected stemness properties
in ovarian cancer cells, the SP assay was performed in the
ovarian cancer cell lines OVCAR-3 and ES-2 cells cultivated
either under normoxia (20% O2) or under hypoxia (1% O2)
for 48 hrs. As shown in Figure 4C hypoxia could enrich SP
cells in both the OVCAR-3 and ES-2 cells, with about 7-fold
increase in the hypoxia cultivated OVCAR-3 cells and 3.7-
fold increase in the hypoxia cultivated ES-2 cells, compared
to the cells cultivated under normxia.
Hypoxia up-regulates HIFs and transcription factors
Hypoxia-inducible factors are a major family of transcrip-
tional factors activated by hypoxia. The effect of hypoxia on
the HIF-1α and HIF-2α expressions was investigated in the
ovarian cancer cell lines. The expression of HIF-1α and HIF-
2α in both the OVCAR-3 and ES-2 cells were significantly
increased in the cells cultivated under hypoxia for 48 hrs,
whereas the cells cultivated under normoxia for 48 hrs were
only weakly positive (Figure 4D). In the normoxia cultures
the level of HIF-2α was higher than the level of HIF-1α. The
expression of both Oct3/4 and Sox2 was significantly
increased in the ES-2 and OVCAR-3 cells cultivated in the
hypoxia condition for 48 hrs, in comparison to the cells cul-
tivated in normoxia condition (Figure 4E).
CD44bright cells display stem-like properties
We discovered during our experiments that the SP cells
separated by FACS were difficult to maintain in vitro, most
probably due to the chemical damage of the Hoechst 33342
dye. In addition, the CD133 expression was not repeatedly
Figure 3 Hypoxia pretreatment increased the sphere and colony formation capability of cells. (A) Figure 3A shows representative spheres
of the cells cultivated under normoxia. (B) Results from three independent experiments show significantly more spheres in the hypoxia pre-
treated groups than the control groups for both cell lines (P< 0.0001). (C) Colony formation assay shows more colonies in the hypoxia pre-
treated cells. (D) Results from three independent experiments show significantly more colonies in the hypoxia pre-treated groups than those in
the normoxia controls (P< 0.0001).
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Figure 4 Hypoxia induced molecular stem-like phenotype. The ovarian cancer cells were maintained under either hypoxia (1% O2) or
normoxia for 48 hrs before additional analyses. (A) Comparatively, there were significantly higher levels of CD44 expression in the OVCAR-3 and
ES-2 cells cultivated under hypoxia. (B) There were also significantly higher levels of CD133 expression in the hypoxia cultivated OVCAR-3 cells,
but the increase of CD133 expression in ES-2 cells was not apparent. (C) SP assay shows also significantly higher number of SP cells in both the
OVCAR-3 and ES-2 cells under hypoxia. (D) The HIF-1α and HIF2-α expressions were induced in the hypoxia cultivated OVCAR-3 and ES-2 cells;
(E) The expressions of Oct3/4 and Sox2 were also correspondingly increased in the hypoxia cultivated OVCAR-3 and ES-2 cells.
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elevated in the ES-2 cells under hypoxia. Therefore, we
decided to further study the CD44bright cells in special con-
sideration of their stemness features in vitro. As shown in
Figure 5A, the CD44bright ovarian cancer cells expressed high
levels of Oct3/4, whereas the CD44dim cells expressed almost
no Oct3/4 in both cell lines. The CD44bright cells expressed
higher levels of Sox2 than the CD44dim cells.
In sphere formation assay, there was almost no qualified
sphere in the CD44dim cells, whereas more spheres were
observed in the CD44bright cells (Figure 5A and B). In
Figure 5 CD44bright cells show stem-like properties. The CD44bright and CD44dim cells were sorted by FACS from the OVCAR-3 and ES-2 cells
before additional Western blotting, sphere and colony formation assays. (A) The CD44bright cells expressed higher levels of Sox2 and Oct3/4 than
the CD44dim cells in both cell lines. (B) Larger spheres from the CD44bright cells and cell clusters not qualified as spheres from the CD44dim cells in
both cell lines are shown (left panel) with a corresponding histogram (right panel). (C) Colony formation assay also shows more colonies in the
CD44bright cells compared to the CD44dim cells in both cell lines (left panel). Three independent colony formation assays show statistically
significantly more colonies in the CD44bright cells, in comparison to the CD44dim cells in both cell lines (P< 0.0001, right panel).
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addition, significantly more colonies could be observed in the
CD44bright cells than the CD44dim cells examined with the
method of colony formation assay (Figure 5C, P< 0.0001).
Discussion
Hypoxia is an inherent characteristic of many solid tumors. It
is well known pathologically that tumor cells tolerate hypoxic
environment. It has been documented in embryonic and
adult stem cell research that hypoxia favors cell growth
in vitro [32-35]. However for cancer cells, it is not fully stud-
ied how hypoxia influences the stem-like properties, although
there has been a great progress in this field [18,36-39]. There-
fore we explored whether hypoxia is a driving force for the
growth of ovarian cancer cells in vitro by performing MTT
experiment. It was found that although the growth difference
was not apparent during the first 48 hrs, the cells in the hyp-
oxic condition grew generally slower that the corresponding
cells under normoxia. The cells cultivated under hypoxia
were further investigated by cell cycle analysis. We discovered
that both ES-2 and OVCAR-3 cell lines experienced a signifi-
cant G0/G1 phase extension under hypoxia for 48 hrs, indi-
cating more quiescent cells under hypoxia. This result is in
line with other tumor cell studies [40-42]. Theoretically, can-
cer stem cells should have a low rate of division and prolif-
eration in their niche which may help to decrease their
chemotherapy and radiotherapy sensitivity [3,8,38].
Then we focused on the effect of hypoxia pretreatment
followed by normoxia cultivation in the ovarian tumor cell
lines, since in present study we found that the cells grew
poor if always placed under hypoxia. The tumor cells were
placed under 1% O2 for 48 hrs as hypoxia pretreatment
group before they were brought back to normoxia, with
the cells always under normoxia as control. We found that
the hypoxia pretreated tumor cells followed by normoxia
cultivation grew significantly faster with significantly
higher infiltration capability in comparison to the cells al-
ways in normoxia. These results indicate that cancer cells
may switch into a more stem-like status when meeting
with hypoxic stress, and develop more aggressive pheno-
type in a manner of selection in a suddenly higher oxygen
environment, such as when tumor cells penetrate into
blood stream or when the “dormant” metastatic solid
tumor cells are mobilized out of bone marrow by till now
un-clarified mechanisms. This may be useful to explain
why hypoxia not only accounts for tissue necrosis, but also
a strong impact on tumor cell biology, with a decreased
sensitivity to apoptotic and other cell-death signals, and an
increased signaling to promote angiogenesis, proliferation
and systemic metastasis capacity when the niche permits
[43-46].
It is known that cancer stem cells residing in epithelial
ovarian cancers can be CD133+ [24] or CD44+ subpopula-
tion cells [26] and these specific markers may be potential
therapeutic targets in this devastating disease. Therefore
the influence of hypoxia on the expression of these two
markers was explored in this study. Our results show that
48 hrs 1% O2 treatment could result in about 2.0-2.7-fold
increase in CD44 expression in both ES-2 and OVCAR-3
cell lines, and about 1.5-fold increase in CD133 expression
in the OVCAR-3 cell line. These results are supported by
other reports that hypoxia helps to expand the CD133+
pancreatic cancer cells [47] and CD133+ glioma stem cells
[48]. It is also reported that hypoxia enriches the CD44
+/CD24- breast cancer stem-like cells [49] and CD44+
murine mesenchymal stem cells [47-50].
To study the effect of hypoxia on stem-like cell pheno-
types, we assessed the fraction of SP cells since SP assay
has been successfully used for identification of cancer
stem-like cells in hepatocellular, breast and ovarian cancers
[14,23,29,51,52]. We found that hypoxia could induce the
SP subpopulation in both OVCAR-3 cells and ES-2 cells.
In addition, the increased SP cells were in parallel with in-
creasing expression levels of HIF-1α and HIF-2α in both
cell lines. It is known that hypoxia often occurs inside solid
tumor and exhibits more severe at the undifferentiated
parts of tumors compared to surrounding tumor or nor-
mal tissues. The initial response of cancer cells to hypoxia
is the activation of hypoxia responsive transcription factor.
The hypoxia inducible factors HIF-1α and HIF-2α are im-
portant factors activated under hypoxia. It has been
reported that HIF-1α expression is increased in other ovar-
ian cancer cell lines in response to hypoxia [42,53], which
are largely in line with our present study. It has been
observed that HIFs influence the phenotypes of tumors by
regulating a number of target genes such as glucose trans-
porters, glycolic enzyme, vascular endothelial cell growth
and growth factors [16,18,54].
The stem-like property impact of hypoxia may be
exerted through transcriptional factors, such as Oct3/4
[16,32] and Sox2 [55]. Oct3/4 and Sox2 are key players in
a transcriptional network for maintenance of embryonic
stem cell and primordial germ cells self-renewal. Several
studies suggest a role for Oct3/4 and Sox2 in sustaining
stem-like property of adult somatic stem cells [56,57]. Our
study verifies that both Oct3/4 and Sox2 were weakly
expressed in the OVCAR-3 and ES2 cell lines, and the
expressions of these proteins were up-regulated upon hyp-
oxia exposure. Furthermore, such increasing levels of
Oct3/4 and Sox2 expression were in parallel with the in-
creasing levels of HIF-1α and HIF-2α expression under
hypoxia. Previous study show that HIF-2α binds to the
promoter of Oct3/4 and directly induces its expression
and activity [58], suggesting a potential role for the inter-
action of HIF-2α and Oct3/4 in ovarian cancer cells upon
hypoxia environment.
Since CD44 has been indicated as a putative surface mar-
ker for cancer stem/progenitor cells in breast and ovarian
cancers [23,26,27,49], and since its expression was
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significantly up-regulated in the OVCAR-3 and ES2 cell
lines under hypoxia, we decided to further analyze whether
CD44 expression was associated with any stem-like prop-
erty in these cells. The expression of Oct3/4 in the
CD44dim cells was almost negative, while its expression in
the corresponding CD44bright cells was dramatically
increased. We performed additional colony formation and
sphere formation assays with the isolated corresponding
CD44dim and CD44bright cells by FACS. Significantly more
spheres and colonies could be repeatedly seen in the
CD44bright cells than those CD44dim cells. Therefore, our
results verify that hypoxia significantly increases the ex-
pression of CD44, and CD44bright cells possess significantly
higher stem-like properties in the ovarian cancer cell lines
OVCAR-3 and ES2.
Conclusion
In summary, our results reveal that ovarian cancer cells
OVCAR-3 and ES2 under hypoxia showed extended
G0/G1 phase, a more quiescent status, and more SP
cells. At the same time these cells under hypoxia
expressed higher levels of CD44, CD133, Oct3/4 and
Sox2. It is further verified that CD44bright cells contrib-
uted to the higher stem-like properties of the cells. If
the cells were cultivated in 1% O2 for 48 hrs and then
brought back to normoxia the cells demonstrated sig-
nificantly higher growth rate with higher infiltration po-
tential and significantly higher colony and sphere
formation capability than those cells always under nor-
moxia. It is concluded that ovarian cancer cells may sur-
vive hypoxia by upgrading their stem-like properties
through up-regulation of stemness-related factors and
behave more aggressively when brought back to higher
oxygen environment.
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